Robotic Procedure for Heart Reveals 100% Clinical Success

Robotic coronary angioplasty has been found to have 100% clinical success rate with zero complications up to 30 days post-procedure as per a R-Evolution clinical study by Robocath - a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, presented at the international EuroPCR conference.

The study of 62 patients across six European centers revealed that coronary angioplasties (cardiac procedure to widen the narrowed blood vessels supplying the heart) using the R-One� robot (robot specifically designed to perform coronary angioplasty) yield 84.5% average reduction in physician radiation exposure with safety and efficacy for patients.

‘R-One � a robotic coronary angioplasty now demonstrates over 95% technical success rate and 100% clinical success rate with zero complications.’

R-One was CE-marked in 2019 and is currently used in Europe, Africa, and China with several benefits being provided to both physicians and patients.

Robots - Future of Cardiology

Moreover, the navigation and accuracy of balloon and stent placement (coronary angioplasty) is improved with the precision of the robotic controls along with providing a safer and more ergonomic working environment.

"This was the first clinical trial in Europe that aimed to assess the safety and efficacy of robotic coronary angioplasty. The results are extremely positive, with a technical success rate of over 95% and a clinical success rate of 100%, all of which show that angioplasties with R-One are safe and effective for patients. In my experience, the average length of a robotic procedure (19.9 � 9.6 min) is roughly the same as that of a manual procedure. Based on these results, the use of the robot genuinely heralds a new age in the treatment of heart conditions, something that has been sorely needed for 30 years given the significant challenges involved in this discipline, particularly the exposure to X-rays," says Prof. Eric Durand, co-principal investigator of the trial.

"We firmly believe that this is just the beginning of vascular robotics and that it will continue to grow with our current, as well as our future, robotic generations, with which the more complex procedures will be performed. Robotics is right at the heart of a sea change within this sector". "There is no doubt in my mind that the future of interventional cardiology lies in integrating robotics," says Lucien Goffart, CEO of Robocath.

Source: Medindia